Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources
News and Community
About us

Teva Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

Loading...

Cancellation by sponsor (163) Cancellation by sponsor (163)
ARTG (123) ARTG (123)
Prescription medicine registration (23)
Australian Public Assessment Report (AusPAR) (7)
Prescription medicine decision summary (3)
Section 14, TGO91 consent (2) Section 14, TGO91 consent (2)
Designation or determination (1) Designation or determination (1)

2025 (11) 2025 (11)
2024 (120) 2024 (120)
2023 (16) 2023 (16)
2022 (13) 2022 (13)
2021 (61) 2021 (61)
2020 (23) 2020 (23)
2019 (11) 2019 (11)
2018 (6) 2018 (6)
2017 (8) 2017 (8)
2016 (25) 2016 (25)
2015 (9) 2015 (9)
2012 (2) 2012 (2)
2011 (4) 2011 (4)
2010 (1) 2010 (1)
2006 (3) 2006 (3)
2002 (7) 2002 (7)
1995 (2) 1995 (2)

Search

Sponsor content

322 result(s) found, displaying 81 to 90

SITAGLIPTIN-TEVA sitagliptin (as malate) 25 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
SITAGLIPTIN-TEVA sitagliptin (as malate) 100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-SITAGLIPTIN sitagliptin (as malate) 100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
SITAGLIPTIN-TEVA sitagliptin (as malate) 50 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-RIVAROXABAN rivaroxaban 10 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-RIVAROXABAN rivaroxaban 15 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-RIVAROXABAN rivaroxaban 2.5 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
SITAGLIPTIN-TV sitagliptin (as malate)100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TE-RIVAROXABAN rivaroxaban 20 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
RIVAROXABAN-TV rivaroxaban 2.5 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Is there anything wrong with this page?

Help us improve this page

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control - external site
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook - external site
(formerly Twitter) - external site
Youtube - external site
Instagram - external site
LinkedIn - external site

Help us improve

We are always looking for ways to improve our website.

Provide feedback - external site

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

Teva Pharma Australia Pty Ltd

Type

Date

Help us improve this page